German CDMO ProBioGen has expanded its GMP protein and viral manufacturing capabilities at its headquarters in Berlin.
To date, the company has commissioned an additional large-scale (1000L) protein production line.
It has also completed the construction phase of its viral manufacturing unit, marking significant progress in the extension.
This strategic expansion will allow the company to keep up with the increasing global demand for biologics.
Catering to the industry's protein production needs
According to ProBioGen, its main reasoning behind the expansion is to "keep up with the increasing global demand for biologics", as the company offers its clients services from cell line development to commercial manufacturing.
The extension of the Berlin site also aims to strengthen ProBioGen's footprint in this niche, while allowing it to better serve the key European market.
The company will use its CHI.RiGHT platform alongside market-approved technologies such as the DirectedLuck transposase and the ADCC enhancement GlymaxX to achieve this.
Viral vector demand continues
With an increasing number of biologics progressing through all stages of development and commercialisation, the need for viral vectors continues to increase.
Therefore, ProBioGen is offering "solutions that go beyond standard processes", according to the company.
It does this by providing tailored cell lines for viral vector and virus-like particle production — including customised stable cell line development for lentiviral (LV) and adeno-associated virus (AAV) production.
With the new expansion, the company will now be able to produce viral vector loads of up to 200L.
"These strategic initiatives mark a major milestone for us as we continue to grow and better fulfill our customer's needs," concluded CEO of ProBioGen, Dr Alfred Merz.